4.7 Article

Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities

Journal

EMERGING MICROBES & INFECTIONS
Volume 8, Issue 1, Pages 1763-1776

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2019.1698271

Keywords

Human lung explant; influenza; antiviral; IFN-alpha subtype; ISG induction; MxA

Funding

  1. German Research Foundation (DFG) [BR 5189/1-1, SFB-TR84, SFB 1009]
  2. Helmholtz-Association (Program Infection and Immunity)
  3. Innovative Medizinische Forschung (IMF)
  4. Interdisciplinary Center for Clinical Research, Muenster

Ask authors/readers for more resources

Influenza is an acute respiratory infection causing high morbidity and mortality in annual outbreaks worldwide. Antiviral drugs are limited and pose the risk of resistance development, calling for new treatment options. IFN-alpha subtypes are immune-stimulatory cytokines with strong antiviral activities against IAV in vitro and in vivo. However, the clinical use of IFN-alpha 2, the only licensed subtype of this multi-gene family, could not prevent or limit IAV infections in humans. However, the other subtypes were not investigated. Therefore, this study evaluated the induction and antiviral potential of all human IFN-alpha subtypes during H3N2 IAV infection in human lung explants. We found that subtypes with weak antiviral activities were preferentially induced during IAV infection in human lungs. Intriguingly, non-induced subtypes alpha 16, alpha 5 and alpha 4 suppressed viral replication up to 230-fold more efficiently than alpha 2. Furthermore, our results demonstrate that subtypes with stronger antiviral activities induce higher expression of IAV-specific restriction factors and that MxA expression is a determinant of the subtype-specific antiviral activity towards H3N2 IAV. These results corroborate that IFN-alpha subtypes exhibit differential antiviral activities and emphasize that subtypes alpha 16, alpha 5 and alpha 4 should be further investigated for the prevention and treatment of severe infections with seasonal H3N2 IAV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available